Canada advises against AstraZeneca for people with rare blood problems

17

Health Canada and the Public Health Agency of Canada have been monitoring the problem since it was mentioned by the EMA as a possible safety concern in April

The Health entity Canada reported late on Tuesday that it recommends that people with a history of capillary leak syndrome not be inoculated with the covid-19 vaccine of the pharmacist AstraZeneca.

The pandemic has shaken the economy and businesses around the world. Learn to invest with EXAME Academy

“Health Canada is updating the product monograph – or label – of AstraZeneca and Covishield Covid-19 vaccines to add capillary leak syndrome as a potential side effect, with a warning for patients with a history of capillary leak syndrome did not receive Covid-19 vaccine from AstraZeneca or Covishield,” the organization said in a statement.

Capillary Leakage Syndrome (CLS) is a very rare condition that causes fluid loss from small blood vessels (capillaries), which results in limb swelling, low blood pressure, blood thickening, and low levels of an important blood protein.

Health Canada and the Public Health Agency of Canada have been monitoring the problem since it was mentioned by the European Medicines Agency (EMA) as a possible safety concern in April, the statement added.

As of June 11, a case of capillary leak syndrome in the wake of an inoculation with AstraZeneca vaccine was reported in the country, Health Canada said.

Earlier this month, the EMA safety committee said the syndrome needs to be added as a new side effect to the label of AstraZeneca’s vaccine, known as Vaxzevria.

  • Do you want to know everything about the pace of vaccination against covid-19 in Brazil and in the world? Sign the EXAM and stay inside.

Thanks for reading the EXAM! How about becoming a subscriber?

Get unlimited access to the best content of your day. In just a few minutes, you create your account and continue reading this article. Come on?

It’s just a moment before you release your access.

digital exam

BRL 3.90/month
  • R$9.90 after the third month.
  • Access whenever and wherever you want.
  • Unlimited access to EXAME Invest, macroeconomics, markets, career, entrepreneurship and technology.

Sign it

annual digital exam

BRL 99.00/year
  • R$ 99.00 in cash or in up to 12 installments. (BRL 8.25 per month)
  • Access whenever and wherever you want.
  • Unlimited access to EXAME Invest, macroeconomics, markets, career, entrepreneurship and technology.

Sign it

palheta smll Canada advises against AstraZeneca for people with rare blood problems

4174353